Chiavarina B, Nokin MJ, Durieux F, Bianchi E, Turtoi A, Peulen O, Peixoto P, Irigaray P, Uchida K, Belpomme D, Delvenne P, Castronovo V, Bellahcène A. Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human bre

Chiavarina B, Nokin MJ, Durieux F, Bianchi E, Turtoi A, Peulen O, Peixoto P, Irigaray P, Uchida K, Belpomme D, Delvenne P, Castronovo V, Bellahcène A. Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget. 2014 Jul 30;5(14):5472-82.

Articles scientifiques

Belpomme D, Irigaray P. Environment as a potential key determinant of the continued increase of prostate cancer incidence in martinique. Prostate Cancer. 2011; doi:10.1155/2011/819010.

Belpomme D, Irigaray P. Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005. JNCI Journal of the National Cancer Institute ; 2010 Apr 7;102(7):506-7.

Irigaray P, Belpomme D. Basic properties and molecular mechanisms of exogenous chemical carcinogens. Carcinogenesis. 2010 Feb;31(2):135-148; doi: 10.1093/carcin/bgp252.

Belpomme D, Irigaray P, Landau-Ossondo M, Martin M. The growing incidence of prostate cancer in the French Caribbean islands, Martinique and Guadeloupe: A possible causal role of pesticides. Int J Oncol. 2009 Aug;35(2):433.

Landau-Ossondo M, Rabia N, Jos-Pelage J, Marquet LM, Isidore Y, Saint-Aimé C, Martin M, Irigaray P, Belpomme D. Why pesticides could be a common cause of prostate and breast cancers in the French Caribbean Island, Martinique. An overview on key mechanisms of pesticide-induced cancer. Biomed Pharmacother. 2009. Jul;63(6):383-395.

Irigaray P, Lacomme S, Mejean L, Belpomme D. Ex vivo study of incorporation into adipocytes and lipolysis-inhibition effect of polycyclic aromatic hydrocarbons. Toxicol Lett. 2009 May 22;187(1):35-9.

Belpomme D, Irigaray P, Ossondo M, Vacque D, Martin M. Prostate cancer as an environmental disease: an ecological study in the French Caribbean islands, Martinique and Guadeloupe. Int J Oncol. 2009 Apr;34(4):1037-44.

Belpomme D., Irigaray P., Hardell L. Electromagnetic fields as cancer-causing agents. Environ. Research, 107 (2008) 289–290.

Belpomme D. Cancer and the environment: Facts, figures, methods and misinterpretations. Editorial. Biomed Pharmacother. 2007 Dec;61(10): 611-613.

Irigaray P., Newby J.A., Clapp R., Hardell L., Howard V., Montagnier L., Epstein S.S., Belpomme D. Lifestyle-related factors and environmental agents causing cancer: An overview. Biomed Pharmacother. 2007 Dec;61(10):640-658.

Irigaray P., Newby J.A., Lacomme S., BelpommeD. Overweight/obesity and cancer genesis: More than a biological link. Biomed Pharmacother. 2007 Dec;61(10):665-678.

Belpomme D., Irigaray P., Hardell L., Montagnier L., Epstein S.S., Clapp R., Sasco A.J. The multitude and diversity of exogenous carcinogens. Environ. Research, 105 (2007) 414–429.

Belpomme D., Irigaray P., Newby J.A., Howard V., Clapp R., Sasco A.J., Hardell L. The growing incidence of cancer: role of lifestyle and screening detection. Int J Oncol. 2007, 30, 1037-1049.

Guillot R, Vadrot N. et al. Inducible nitric oxide synthase (iNOS) could be partially responsible for HuH7 human hepatoma cell resistance to interferon g-induced apoptosis", 2005, soumis pour publication.

Belpomme D. Cancers, le poids de l'environnement. Encyclopaedia Universalis, Science au présent, 2005.

Belpomme D., The contribution of the physico-chemical environment to the genesis of cancer: what extent and how to measure it? Bull Mem Acad R Med Belg. 2005;160(3-4):163-180.

Belpomme D. Editorial. Oncology, 2004, 6 (4).

Guillot R, Legrand A. et al. Study of the effects of interferon a on several human hepatoma cell lines. Liver International, 2004, 24: 149-160.

Belpomme D., Krakowski I., Beauduin M., Petit T., Canon J.L., Janssens J., Gauthier S., De Pauw A., Moreau V., Kaytalire L. Gemcitabine combined with Cisplatin in patients with epithelial ovarian cancer as first-line treatment: A phase II study report. Gynecologic Oncology 2003, 91(1): 32-38.

Khodadad K., Sturtz F., Pujade-Lauraine E., Belpomme D. Over 25% 5-year-overall survival (OS) in patients with metastatic breast carcinoma (MBS) receiving the VVF protocol in addition to conventional treatments. Proc. Am. Soc. Clin. Onc. Mai 2001.

Pivot X., Kelly, Tortochaux J., Belpomme D., Humblet Y., Domenge C., Johnston A., Clendeninn N., Penning C., Schneider M. A phase III trial of nolatrexed versus methotrexate in patients (pts) with advanced or recurrent squamous cell carcinoma of the head and neck. Annals Oncology 2001, 12 (11): 1595-9.

Belpomme D., Pujade-Lauraine E., Gauthier S., Krakowski I., Frenay M., Facchini, Goudier M.J., Gousset C., Sturtz F. Verapamil increases the survival of patients with anthracycline resistant metastatic breast carcinoma. Annals Oncology 2000, 11 : 1471-1476.

Haut du site
Close blockOpen block

Nos contacts

Coordonnées de l'ARTAC :

57/59 rue de la Convention
75015 PARIS